Improving prostate cancer treatment
About Nicholas James
Prostate cancer claims 10,000 lives in the UK every year and is the most common cancer amongst UK men. If men have advanced, spreading prostate cancer they can be given a type of chemotherapy known as androgen suppression, which involves blocking the action of the male sex hormones. But the cancer often returns.
Professor James is carrying out a trial to see whether using certain drugs together with androgen suppression can prevent the disease from coming back and improve a man's survival and quality of life.
The trial is called STAMPEDE - Systematic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy. A pilot phase of the trial successfully showed that these drugs could be used together safely and effectively. Now Professor James's team are recruiting 3,300 men for the main trial. STAMPEDE will look at 5 different drug combinations alongside androgen suppression, and also compare these therapies with treatment involving androgen suppression alone.
If STAMPEDE shows that a new drug combination is more effective than existing androgen suppression therapy, this could help prostate cancer patients in the UK and all over the world.
Find out more about androgen suppression therapy on CancerHelp UK, our patient information website.
Listen to Professor James talking about progress in prostate cancer and the STAMPEDE trial in our December 2013 podcast.
Other research projects by Nicholas James
CRUK/06/019: STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy. A three-stage multi-arm, randomised controlled trial
Funding period: 01 October 2006 to 30 September 2017
CRUK/09/021: TUXEDO - Phase I/II feasibility study of cetuximab with or without cisplatin with concurrent radiotherapy in muscle invasive bladder cancer
Funding period: 01 February 2010 to 29 February 2016